HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

chloroeremomycin

structure given in first source

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycoconjugates: 1353
  - Glycopeptides: 1928
    - Vancomycin: 10299
      - chloroeremomycin: 3
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Glycopeptides: 1928
    - Vancomycin: 10299
      - chloroeremomycin: 3

Experts

1.	Havlichek, Daniel H: 1 article (01/2015)
2.	Mitra, Subhashis: 1 article (01/2015)
3.	Saeed, Usman: 1 article (01/2015)
4.	Stein, Gary E: 1 article (01/2015)
5.	Courvalin, Patrice: 1 article (01/2004)
6.	Tulkens, Paul M: 1 article (01/2004)
7.	Van Bambeke, Françoise: 1 article (01/2004)
8.	Van Laethem, Yves: 1 article (01/2004)
9.	Allen, Norris E: 1 article (01/2003)
10.	Nicas, Thalia I: 1 article (01/2003)

Related Diseases

1.	Infections 01/01/2003 - "Oritavancin is the N-alkyl-p-chlorophenylbenzyl derivative of chloroeremomycin (LY264826) and is currently in phase III clinical trials for use in Gram-positive infections. " 01/01/2015 - "Oritavancin, a semisynthetic derivative of the glycopeptide antibiotic chloroeremomycin, received the US Food and Drug Administration approval for the treatment of acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria in adults in August 2014. "
2.	Soft Tissue Infections 01/01/2004 - "Two are being currently evaluated for skin and soft tissue infections and are in phases II/III. The first, oritavancin (LY333328), is the 4'-chlorobiphenylmethyl derivative of chloroeremomycin, an analogue to vancomycin. "

Related Drugs and Biologics

1.	oritavancin
2.	Vancomycin
3.	Glycopeptides
4.	Anti-Bacterial Agents (Antibiotics)